IRIS
LAZZARIN, ADRIANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.709
NA - Nord America 3.270
EU - Europa 1.983
SA - Sud America 1.023
AF - Africa 62
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 1
Totale 10.054
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.172
SG - Singapore 1.526
CN - Cina 1.095
BR - Brasile 863
SE - Svezia 730
HK - Hong Kong 554
RO - Romania 268
IT - Italia 257
VN - Vietnam 247
RU - Federazione Russa 208
DE - Germania 177
FI - Finlandia 74
GB - Regno Unito 69
AR - Argentina 68
IN - India 63
CA - Canada 51
MX - Messico 36
BD - Bangladesh 35
PL - Polonia 35
ID - Indonesia 33
EC - Ecuador 32
ZA - Sudafrica 32
NL - Olanda 30
TR - Turchia 29
AT - Austria 27
CO - Colombia 22
IE - Irlanda 20
IQ - Iraq 20
JP - Giappone 20
ES - Italia 19
FR - Francia 17
PK - Pakistan 15
LT - Lituania 14
UZ - Uzbekistan 13
VE - Venezuela 11
AE - Emirati Arabi Uniti 10
UA - Ucraina 10
MA - Marocco 9
CL - Cile 8
CZ - Repubblica Ceca 6
PY - Paraguay 6
SA - Arabia Saudita 6
TN - Tunisia 6
BE - Belgio 5
BO - Bolivia 5
DZ - Algeria 5
EG - Egitto 5
EU - Europa 5
MD - Moldavia 5
IL - Israele 4
IR - Iran 4
KW - Kuwait 4
NP - Nepal 4
UY - Uruguay 4
JO - Giordania 3
OM - Oman 3
PA - Panama 3
PE - Perù 3
TH - Thailandia 3
BB - Barbados 2
BG - Bulgaria 2
CI - Costa d'Avorio 2
DO - Repubblica Dominicana 2
GE - Georgia 2
KE - Kenya 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LB - Libano 2
NI - Nicaragua 2
PH - Filippine 2
PS - Palestinian Territory 2
AL - Albania 1
AM - Armenia 1
AU - Australia 1
AZ - Azerbaigian 1
BH - Bahrain 1
BN - Brunei Darussalam 1
CH - Svizzera 1
DK - Danimarca 1
GA - Gabon 1
GF - Guiana Francese 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
LV - Lettonia 1
MK - Macedonia 1
MN - Mongolia 1
NO - Norvegia 1
PT - Portogallo 1
QA - Qatar 1
RS - Serbia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 10.054
Salva come PNG Salva come JPEG
Città #
Dallas 1.425
Singapore 619
Hong Kong 551
Shanghai 270
Ashburn 264
Hefei 231
Lawrence 219
Princeton 219
Beijing 164
New York 135
Milan 108
Moscow 106
Ho Chi Minh City 92
São Paulo 88
Los Angeles 78
Helsinki 53
Nuremberg 53
Hanoi 52
Boardman 44
Munich 41
Warsaw 33
Guangzhou 28
Pune 23
Rome 23
Curitiba 21
Washington 21
Johannesburg 20
Montreal 20
Tokyo 20
Seattle 19
Chennai 18
Denver 18
Santa Clara 18
Atlanta 17
Belo Horizonte 17
Mexico City 17
Rio de Janeiro 17
Brooklyn 16
Dublin 16
Orem 15
Turku 15
Stockholm 14
Brasília 13
Campinas 13
Manchester 13
Poplar 13
Shenzhen 13
Tashkent 13
Amsterdam 12
Ankara 12
London 12
Vienna 12
Boston 11
Guayaquil 11
Houston 11
Porto Alegre 11
Quito 11
Toronto 11
Chicago 10
Goiânia 10
Reston 10
The Dalles 10
Haiphong 9
Phoenix 9
Cesano Boscone 8
Hải Dương 8
Salvador 8
Betim 7
Buenos Aires 7
Da Nang 7
Frankfurt am Main 7
Istanbul 7
Kassel 7
Sorocaba 7
São José do Rio Preto 7
Tianjin 7
Charlotte 6
Columbus 6
Guarulhos 6
Ha Long 6
Nova Iguaçu 6
Quanzhou 6
Querétaro 6
Vitória 6
Belém 5
Bogotá 5
Can Tho 5
Cape Town 5
Chisinau 5
Dhaka 5
Erbil 5
Joinville 5
Mogi das Cruzes 5
Pouso Alegre 5
Santo André 5
Vitória da Conquista 5
Wolfhagen 5
Wuyuan 5
Xi'an 5
Agawam 4
Totale 5.702
Salva come PNG Salva come JPEG
Nome #
The 118I reverse transcriptase mutation is the only independent genotypic predictor of virologic failure to a stavudine-containing salvage therapy in HIV-1-infected patients 1.305
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors 131
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 106
A comparision of brain biopsy and CSF-PCR in the diagnosis of CNS lesions in AIDS patients 105
48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study 97
Candidemia in COVID-19 patients: incidence and characteristics in a prospective cohort compared to historical non-COVID-19 controls 94
Biobanking for COVID-19 research 84
Marked Decrease in Lymphocyte Count in HIV/Hepatitis C Virus (HCV)-Coinfected Patients with Advanced Liver Disease during Anti-HCV Treatment with Direct-Acting Antiviral Regimens Including Ribavirin 79
Publisher Correction: Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 (Scientific Reports, (2020), 10, 1, (21291), 10.1038/s41598-020-78039-1) 78
HAART simplification with lopinavir/ritonavir monotherapy in HIV/HCV co-infected patients starting anti-HCV treatment: a randomised pilot study (KaMon study) 72
Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy 72
Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort 72
Circulating cathodic antigen (CCA) urine rapid test for diagnosis of Schistosoma mansoni infestation: preliminary data of a cohort study of Egyptian patients coming from an endemic area 72
HLA-associated susceptibility to AIDS: HLA B35 is a major risk factor for Italian HIV-infected intravenous drug addicts 71
Analytical treatment interruption in chronic HIV-1 infection: Time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study) 70
Analysis of the faecal microbiome during analytical treatment interruption in people with chronic HIV infection and long-lasting virological suppression (APACHE study) 69
Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients 64
Bictegravir 64
Beneficial effects of cART initiated during primary and chronic HIV-1 infection on immunoglobulin-expression of memory B-cell subsets 63
A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study 62
A study of cellular immunity in newborns after prevention of respiratory distress syndrome (RDS). 61
Cerebrospinal fluid beta 2-microglobulin in AIDS related central nervous system involvement. 60
Anti-hepatitis C virus treatment may prevent the progression of liver fibrosis in non-responder human immunodeficiency virus/hepatitis C virus coinfected patients 60
Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice 57
Experiences with immunomodulant agents in HIV infections 57
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 57
SARS-CoV-2 IgG/IgM Rapid Test as a Diagnostic Tool in Hospitalized Patients and Healthcare Workers, at a large Teaching Hospital in northern Italy, during the 2020 COVID-19 Pandemic 57
Darunavir for the treatment of HIV infection 56
Evaluation of HIV transmission clusters among natives and foreigners living in Italy 56
ABC of AIDS: Treatment of infections and antiviral agents 56
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 55
An observational, retrospective analysis evaluating switching to raltegravir plus abacavir/lamivudine in HIV-1-infected patients: the ORASWIRAL study 54
Dynamics of HIV-1 POL antibodies after ART in chronic HIV-1 infection 54
Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial 53
Cancer Risk and Use of Protease Inhibitor or Nonnucleoside Reverse Transcriptase Inhibitor-Based Combination Antiretroviral Therapy: The D:A:D Study 52
Point-of-care testing for hepatitis C virus infection at an Italian dental clinic: portrait of the pilot study population 52
Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients 52
VIRO-immunological outcomes after 13-valent pneumococcal vaccination in HIV-1-infected individuals on stable virological suppression 51
Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: A sub-study of the NEAT001/ANRS143 randomized trial 51
Longitudinal evaluation of occult Hepatitis B infection in HIV-1 infected individuals during highly active antiretroviral treatment interruption and after HAART resumption 50
Long-term effect of highly active antiretroviral therapy on cervical lesions in HIV-positive women. 50
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 50
Monotherapy with atazanavir as a simplification strategy: results from an observational study. 49
Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman 49
Brief Report: Hyperbilirubinemia Is Associated With a Decreased Risk of Carotid Atherosclerosis in HIV-Infected Patients on Virological Suppression 49
Residual viremia in HIV-infected patients who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor based regimen 49
Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfected patients 48
HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe 48
Incidence and Predictors of Serological Treatment Response in Early and Late Syphilis Among People Living With HIV 47
Western blot in treated people with HIV-1 chronic infection: frequency of negative HIV-1 pol genes 47
Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents 47
Early Diagnosis and Linkage to Care: an Experience over 14 years of Point of Care Rapid HIV Testing 46
Immunological status in heroin addicts: effects of methadone maintenance treatment 46
Early diagnosis of HIV infection in infants 46
Analysis of impediments to the maintenance in care of people with HIV in Italy 46
Brief Report: New HIV Diagnoses in PrEP-Experienced and PrEP-Naive Persons in the ICONA Cohort 45
Evolution of the E2 region of hepatitis C virus in an infant infected by mother-to-infant transmission 45
Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen 45
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011 45
Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption 44
INCREASED RISK OF DEATH AMONG HIV/HCV CO-INFECTED PATIENTS WITH NON-HODGKIN'S LYMPHOMA 44
Dynamics of adaptive and innate immunity inpatients treated during primary human immunodeficiency virus infection: Results from Maraviroc in HIV Acute Infection (MAIN) randomized clinical trial 44
Hepatitis delta infection among persons living with HIV in Europe 44
Benefits of a 12 week physical activity programme on muscle and bone health in people living with HIV 43
Impact of HAART on liver histology of HIV/HCV coinfected patients 43
Point-of-care testing for hepatitis C virus infection at alternative and high-risk sites: An Italian pilot study in a dental clinic 43
Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients 43
Maraviroc 150mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study 43
Liver-related death among HIV/hepatitis C virus-co-infected individuals: Implications for the era of directly acting antivirals 43
Evolving treatment implementation among HIV- infected pregnant women and their partners: Results from a national surveillance study in Italy, 2001-2015 42
Long-term suppression of viral replication in HIV-related lymphoma survivors: a case-control study 42
Evaluation of HIV-DNA and residual viremia levels through week 96 in HIV-infected individuals who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor-based regimen 42
Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: A prospective international cohort study 41
Drop in CD4+ Counts Below 200 Cells/μL After Reaching (or Starting From) Values Higher than 350 Cells/μL in HIV-Infected Patients With Virological Suppression 41
Naive HIV/HCV-coinfected patients have higher intrahepatic pro-inflammatory cytokines than coinfected patients treated with antiretroviral therapy 40
Immune recovery and T cell subset analysis during effective treatment with maraviroc 40
The Less Drugs Regimens (LDRs) therapy approach in HIV-1: an Italian expert panel perspective for the long-term management of HIV-1 infection. 40
Zidovudine and frequency of HIV-induced diffuse leukoencephalopathy 40
Estimated glomerular filtration rate trajectories in HIV-infected subjects treated with different ritonavir-boosted protease inhibitors and tenofovir disoproxil fumarate or abacavir 40
Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimens 40
Morphogenesis, evolution and prognostic significance of lymphatic tissue lesions in HIV infection 39
Clinical and epidemiological aspects of the first 50 cases of AIDS in Milan 39
Clinical, virologic, and immunologic outcomes in lymphoma survivors and in cancer-free, HIV-1-infected patients: a matched cohort study. 39
Cytomegalovirus pneumonia in AIDS patients: value of cytomegalovirus culture from BAL fluid and correlation with lung disease 38
Survival of HIV-1 Infected Multidrug-Resistant Patients Recycling Enfuvirtide After a Previous Failure 37
Italian Guidelines for the Use of Antiretroviral Agents and the Diagnostic-clinical Management of HIV-1 Infected Persons 37
Hyaluronic Acid Levels Predict Risk of Hepatic Encephalopathy and Liver-Related Death in HIV/Viral Hepatitis Coinfected Patients 37
Long-lasting CCR5 internalization by antibodies in a subset of long-term non progressors: a possible protective effect against disease progression 37
Determination of human papillomavirus (HPV) load and type in high-grade cervical lesions surgically resected from HIV-infected women during follow-up of HPV infection. 37
Cytomegalovirus infection of the central nervous system in patients with aids: Diagnosis by DNA amplification from cerebrospinal fluid 37
Presence of multiple genotypes in subjects with HPV-16 infection is highly associated with anal squamous intraepithelial lesions in HIV-1 infected males 37
Reduced frequency of HIV-induced brain lesions in AIDS patients treated with zidovudine 37
THE EFFECT OF HIV-1 IN DECREASING MITOCHONDRIAL DNA IN PERIPHERAL BLOOD MONONUCLEAR CELLS OVERCOMES THE TOXIC EFFECT OF ANTIRETROVIRAL THERAPY (ART) 37
Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium 36
GB Virus C and Survival in Persons with HIV Infection 36
Risk of HIV-related diseases in heterosexuals importing infection from Zaire 36
Pharmacokinetics of the raltegravir/maraviroc/etravirine combination 36
Plasma fibroblast growth factor 23 and osteocalcin serum levels are associated with cardiovascular risk in HIV-1-infected patients receiving antiretroviral treatment. 36
Italian consensus statement on management of HIV-infected individuals with advanced disease naïve to antiretroviral therapy 36
T-lymphocyte subsets and delayed type hypersensitivity as classification parameters for HIV infection among drug-addicts 36
Totale 6.450
Salva come PNG Salva come JPEG
Categoria #
all - tutte 84.308
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 84.308
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202184 0 0 0 0 0 14 11 57 1 0 1 0
2021/2022145 0 0 0 77 6 8 8 13 10 7 3 13
2022/20231.203 483 292 102 7 10 125 33 85 48 1 11 6
2023/2024605 7 29 81 49 45 137 13 68 0 15 80 81
2024/20253.101 375 58 37 81 83 256 711 232 487 360 162 259
2025/20264.972 718 880 1.425 1.260 633 56 0 0 0 0 0 0
Totale 10.321